Institut für Versorgungsforschung in der Onkologie

Koblenz 56068

1 studies enrolling now · 5 studies all time

What they study most

Breast Cancer, HER2-Positive Primary Breast Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer, Metastatic Urothelial Cancer, Myelodysplastic Syndrome, Residual Invasive Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Recruiting now
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) — Completed
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed